Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$606.8M
26M shares
52-week range
$14.42 – $26.74
72% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
2.2
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
www.orthopediatrics.comNo one on the platform currently holds KIDS.
No tracked institution reports a position in KIDS as of their last filing.
No one on the platform has traded KIDS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 15.4% | 27.2% | ||||
| Profit Margin % | -16.8% | -13.0% | -18.8% | |||
| Free Cash Flow Margin % | -6.8% | -22.7% | -27.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $267M | +13.7% | $-1.22 | $-1.24–$-1.21 | — | 4 |
| 2027 | $299M | +11.9% | $-0.82 | $-0.83–$-0.81 | — | 5 |
| 2028 | $334M | +11.6% | $-0.38 | $-1.13–$0.35 | — | 4 |
| 2029 | $373M | +11.9% | $0.19 | $0.19–$0.19 | 122.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.30 | $-0.26 | +14.0% |
| 2026-04-30 | $-0.38 | $-0.42 | -10.5% |
| 2026-02-26 | $-0.37 | $-0.43 | -16.2% |
| 2025-10-28 | $-0.26 | $-0.24 | +7.7% |
| 2025-08-05 | $-0.17 | $-0.11 | +35.3% |
| 2025-05-07 | $-0.26 | $-0.39 | -50.0% |
| 2025-03-04 | $-0.33 | $-0.29 | +12.1% |
| 2024-11-06 | $-0.12 |
| $-0.18 |
| -50.0% |
| $521M |
| — |
| LABStandard BioTools Inc. | $0.69 | -0.89% | $270M | — |
| RXSTRxSight, Inc. | $5.62 | -7.94% | $233M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KIDS Saw this on Equibles. Orthopediatrics Corp 10% owner Squadron Capital LLC reported selling 302,369 KIDS shares on September 10, 2026, worth about $6.35 million, in a non-derivative Form 4.
View on StockTwits ↗
$GPUS Will delist by the end of September at this rate! 🤣 What a fkin piece of shxt this guy is! 💩 Had to block @WC25 for being an absolute bulltard… After this delists, we just have $KIDS and $SRXH left on the “ultimate scam stock” list! 🤣😂
View on StockTwits ↗
$KIDS OrthoPediatrics Corp. goes nationwide with its 3P Pediatric Plating Platform Hip System — Locking Proximal Femur Plates + Beam Screw constructs for infant/child/adolescent hip trauma and deformity cases. 350+ implantations during limited release preceded the launch. First product in a planned multi-system platform; no revenue forecast or launch schedule for follow-ons disclosed yet. Watch trauma-and-deformity revenue growth and active surgeon-user counts as the real signal. $KIDS #MedTech #Pediatrics https://prismmarketview.com/orthopediatrics-expands-pediatric-hip-surgery-options-with-nationwide-3p-system-launch/
View on StockTwits ↗
@IsabellaDC $PAYS them $KIDS $ATRC been nice @Jblack500 @BustaCapital @WAJeff @cynicaloptimist @No_Face_character
View on StockTwits ↗@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $KIDS
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-4-orthopediatrics-corp-stock/ $KIDS OrthoPediatrics Earnings Transcript
View on StockTwits ↗
$KIDS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 • Reported revenue of $70.51M up 15.43% YoY • OrthoPediatrics Corp. is increasing its full year 2026 revenue guidance to $265.0 million to $269.0 million, while reiterating expectations for $25.0 million in adjusted EBITDA and achieving cash-flow breakeven in 2026.
View on StockTwits ↗
$KIDZ $KIDS kidz_424b4.htm https://www.sec.gov/Archives/edgar/data/2022308/000147793226004453/kidz_424b4.htm
View on StockTwits ↗
$KIDS It appears to be a trading halt following a surge above the $1 level.
View on StockTwits ↗$KIDZ Wake up, wake up—why is everyone still asleep? I’ve woken up from the dream. Onward to $3.😘😘😘😘 🚨🚨🚨🚨🚨🚨 $KIDS 🚨🚨🚨🚨
View on StockTwits ↗
$KIDS sold for a 10%+ gain. Seems solid company and likely upside from here, but not a high confidence name for me. Dumping back into $TMDX and $TTD who are oversold, imo.
View on StockTwits ↗
$KIDS Current Stock Price: $17.32 Contracts to trade: $20.0 KIDS May 15 2026 Call Entry: $0.11 Exit: $0.20 ROI: 81% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$KIDS Nice run. Thinking it may retrace a bit soon, and likely will add on weakness.
View on StockTwits ↗$KIDS i sold shortly after but recently back in. Hoping this Q ER represents the bottom.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.